Premium
Combination Therapy with β‐Adrenergic Receptor Antagonists and Phosphodiesterase Inhibitors for Chronic Heart Failure
Author(s) -
Tassell Benjamin W.,
Radwanski Przemyslaw,
Movsesian Matthew,
Munger Mark A.
Publication year - 2008
Publication title -
pharmacotherapy: the journal of human pharmacology and drug therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.227
H-Index - 109
eISSN - 1875-9114
pISSN - 0277-0008
DOI - 10.1592/phco.28.12.1523
Subject(s) - phosphodiesterase , medicine , heart failure , pharmacology , adrenergic , clinical trial , pharmacotherapy , cyclic adenosine monophosphate , adverse effect , combination therapy , receptor , cardiology , endocrinology , enzyme , chemistry , biochemistry
Rational use of phosphodiesterase inhibitors represents an ongoing controversy in contemporary pharmacotherapy for he art failure. In randomized clinical trials, phosphodiesterase inhibitors increased cardiac output at the expense of worsening the rates of sudden cardiac death and cardiovascular mortality. Preliminary findings from ongoing clinical and preclinical investigations of phosphodiesterase activity suggest that combined use of phosphodiesterase inhibitors with β‐adrenergic antagonists may prevent these adverse outcomes. Compartmentation of cyclic adenosine 3′,5′‐monophosphate signaling may prove critical in determining myocardial response to combination therapy.